Literature DB >> 23629703

Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit.

Teysir Halaby1, Nashwan Al Naiemi, Jan Kluytmans, Job van der Palen, Christina M J E Vandenbroucke-Grauls.   

Abstract

Selective decontamination of the digestive tract (SDD) selectively eradicates aerobic Gram-negative bacteria (AGNB) by the enteral administration of oral nonabsorbable antimicrobial agents, i.e., colistin and tobramycin. We retrospectively investigated the impact of SDD, applied for 5 years as part of an infection control program for the control of an outbreak with extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae in an intensive care unit (ICU), on resistance among AGNB. Colistin MICs were determined on stored ESBL-producing K. pneumoniae isolates using the Etest. The occurrence of both tobramycin resistance among pathogens intrinsically resistant to colistin (CIR) and bacteremia caused by ESBL-producing K. pneumoniae and CIR were investigated. Of the 134 retested ESBL-producing K. pneumoniae isolates, 28 were isolated before SDD was started, and all had MICs of <1.5 mg/liter. For the remaining 106 isolated after starting SDD, MICs ranged between 0.5 and 24 mg/liter. Tobramycin-resistant CIR isolates were found sporadically before the introduction of SDD, but their prevalence increased immediately afterward. Segmented regression analysis showed a highly significant relationship between SDD and resistance to tobramycin. Five patients were identified with bacteremia caused by ESBL-producing K. pneumoniae before SDD and 9 patients thereafter. No bacteremia caused by CIR was found before SDD, but its occurrence increased to 26 after the introduction of SDD. In conclusion, colistin resistance among ESBL-producing K. pneumoniae isolates emerged rapidly after SDD. In addition, both the occurrence and the proportion of tobramycin resistance among CIR increased under the use of SDD. SDD should not be applied in outbreak settings when resistant bacteria are prevalent.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23629703      PMCID: PMC3697390          DOI: 10.1128/AAC.02634-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital.

Authors:  J C Lucet; D Decré; A Fichelle; M L Joly-Guillou; M Pernet; C Deblangy; M J Kosmann; B Régnier
Journal:  Clin Infect Dis       Date:  1999-12       Impact factor: 9.079

2.  Detection of beta-lactamase-mediated resistance.

Authors:  D M Livermore; D F Brown
Journal:  J Antimicrob Chemother       Date:  2001-07       Impact factor: 5.790

3.  Selective decontamination of the gastrointestinal tract as an infection control measure.

Authors:  M E Taylor; B A Oppenheim
Journal:  J Hosp Infect       Date:  1991-04       Impact factor: 3.926

4.  Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258.

Authors:  Tatiana Bogdanovich; Jennifer M Adams-Haduch; Guo-Bao Tian; Minh Hong Nguyen; Eun Jeong Kwak; Carlene A Muto; Yohei Doi
Journal:  Clin Infect Dis       Date:  2011-08       Impact factor: 9.079

5.  Short-term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumannii.

Authors:  C Agustí; M Pujol; M J Argerich; J Ayats; M Badía; M A Domínguez; X Corbella; J Ariza
Journal:  J Antimicrob Chemother       Date:  2002-01       Impact factor: 5.790

6.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.

Authors:  V I Enne; D M Livermore; P Stephens; L M Hall
Journal:  Lancet       Date:  2001-04-28       Impact factor: 79.321

7.  A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage.

Authors:  Lisa Saidel-Odes; Hana Polachek; Nehama Peled; Klaris Riesenberg; Francisc Schlaeffer; Yafa Trabelsi; Seada Eskira; Baha Yousef; Rozalia Smolykov; Shlomi Codish; Abraham Borer
Journal:  Infect Control Hosp Epidemiol       Date:  2011-11-30       Impact factor: 3.254

8.  Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains.

Authors:  Jerome R Lo-Ten-Foe; Anne Marie G A de Smet; Bram M W Diederen; Jan A J W Kluytmans; Peter H J van Keulen
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

9.  Intestinal decontamination for control of nosocomial multiresistant gram-negative bacilli. Study of an outbreak in an intensive care unit.

Authors:  C Brun-Buisson; P Legrand; A Rauss; C Richard; F Montravers; M Besbes; J L Meakins; C J Soussy; F Lemaire
Journal:  Ann Intern Med       Date:  1989-06-01       Impact factor: 25.391

10.  Selective decontamination in European intensive care patients.

Authors:  Evelien A N Oostdijk; Bastiaan H J Wittekamp; Christian Brun-Buisson; Marc J M Bonten
Journal:  Intensive Care Med       Date:  2012-04       Impact factor: 17.440

View more
  53 in total

1.  Colistin resistance during selective digestive tract decontamination is uncommon.

Authors:  D F Zandstra; J H Rommes; M A de la Cal; L Silvestri; N Taylor; H K F van Saene
Journal:  Antimicrob Agents Chemother       Date:  2014       Impact factor: 5.191

2.  Carbapenem-Resistant Enterobacteriaceae: Laboratory Detection and Infection Control Practices.

Authors:  Eva-Brigitta Kruse; Ute Aurbach; Hilmar Wisplinghoff
Journal:  Curr Infect Dis Rep       Date:  2013-10-12       Impact factor: 3.725

3.  Ventilator-associated pneumonia prevention: response to Silvestri et al.

Authors:  Girish B Nair; Michael S Niederman
Journal:  Intensive Care Med       Date:  2015-03-31       Impact factor: 17.440

4.  Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection.

Authors:  Young Kyung Yoon; Jin Woong Suh; Eun-Ji Kang; Jeong Yeon Kim
Journal:  Ann Med       Date:  2019-09-13       Impact factor: 4.709

Review 5.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

6.  Antipathy against SDD is justified: Yes.

Authors:  Jean-François Timsit; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2018-06-07       Impact factor: 17.440

7.  Selective digestive tract decontamination and spread of colistin resistance: antibiotic prophylaxis is not a substitute for hygiene.

Authors:  Wolfgang A Krueger; Alexandra Heininger; Béatrice Grabein; Klaus Unertl; Miguel Sánchez-García
Journal:  Antimicrob Agents Chemother       Date:  2014-06       Impact factor: 5.191

8.  SDD and colistin resistance: end of a dream?

Authors:  Matteo Bassetti; Elda Righi
Journal:  Intensive Care Med       Date:  2014-05-27       Impact factor: 17.440

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak.

Authors:  Teysir Halaby; Emre Kucukkose; Axel B Janssen; Malbert R C Rogers; Dennis J Doorduijn; Adri G M van der Zanden; Nashwan Al Naiemi; Christina M J E Vandenbroucke-Grauls; Willem van Schaik
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.